Pharvaris (PHVS) Change in Account Payables (2020 - 2026)
Pharvaris (PHVS) posted Change in Account Payables of -$5.5 million for Q1 2026, down 221.57% on a QoQ basis from $4.6 million in Q4 2025, and down 1462.15% year-over-year from $406477.4 in Q1 2025.
Pharvaris (PHVS) Change in Account Payables (2020 - 2026) Analysis & Trends
Pharvaris' Change in Account Payables history runs 7 years deep, the most recent figure standing at -$5.5 million for Q1 2026.
- Quarterly Change in Account Payables fell 1462.15% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.2 million (down 272.0% YoY) and the FY2025 annual result came in at -$29272.3, down 101.64% from the prior year.
- Change in Account Payables was -$5.5 million for Q1 2026 at Pharvaris, down from $4.6 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1657.9 billion in Q3 2023 and bottomed at -$1658.4 billion in Q2 2023.
- A 5-year average of -$30.2 million and a median of $859138.2 in 2025 frame the typical range for Change in Account Payables.
- Peak annual rise in Change in Account Payables reached 56176968.41% in 2023, while the deepest fall reached 188589424.78% in 2023.
- Pharvaris' Change in Account Payables stood at -$713969.1 in 2022, then plunged by 189.52% to -$2.1 million in 2023, then soared by 119.05% to $393783.8 in 2024, then soared by 1056.55% to $4.6 million in 2025, then plunged by 221.57% to -$5.5 million in 2026.
- Business Quant data shows PHVS's Change in Account Payables at -$5.5 million in Q1 2026, $4.6 million in Q4 2025, and -$5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Pharvaris | 2.17 Bn | 1.88 Bn | - | -5.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.54 Mn |
| Mar 31, 2026 | -5.54 Mn |
| Dec 31, 2025 | 4.55 Mn |
| Dec 31, 2025 | 4.55 Mn |
| Sep 30, 2025 | -5.10 Mn |
| Sep 30, 2025 | -5.10 Mn |
| Jun 30, 2025 | 859,138.16 |
| Jun 30, 2025 | 859,138.16 |
| Mar 31, 2025 | -354,436.67 |
| Mar 31, 2025 | -354,436.67 |
| Dec 31, 2024 | 393,783.82 |
| Dec 31, 2024 | 393,783.82 |
| Sep 30, 2024 | 1.35 Mn |
| Sep 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | -2.79 Mn |
| Jun 30, 2024 | -2.79 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Dec 31, 2023 | -2.07 Mn |
| Dec 31, 2023 | -2.07 Mn |